The phrase "aggressive trial" is correct and usable in written English.
It can be used in contexts related to testing, experimentation, or legal proceedings where a forceful or assertive approach is taken.
Example: "The researchers conducted an aggressive trial to determine the effectiveness of the new drug under extreme conditions."
Alternatives: "intensive trial" or "assertive trial".
He has a reputation for aggressive trial representation.
"We've seen a much more aggressive trial bar since the tobacco settlement.
The protocols for them took years of aggressive trial and error to develop, with hundreds of patients suffering immensely, and yet scientists still do not fully understand how the body accepts foreign grafts.
With newer information indicating more favorable outcomes of intensive care therapy for lung cancer patients, intensivists increasingly are willing to initiate an aggressive trial of this therapy.
We have previously noted that an early aggressive trial of ICU support may actually improve satisfaction and subsequently make it easier for families to change the goal of care to comfort, knowing full well that everything possible was done [ 8, 40].
Don't be fooled by advertising slogans, such as "former deputy district attorney" or "aggressive trial lawyer".
Jio launched in September 2016 with an aggressive free trial offer, picking up 100 million customers in just six months.
The ongoing TEAR (Treatment of Early Aggressive RA) trial in the US is a blinded RCT using a 'treatment to target' approach, with results expected in the near future.
In the more recent time period, use of OS decreased in both indolent (28% versus 0%, P = 0.042) and aggressive NHL trials (81% versus 36%, P = 0.006).
In contrast, studies show that patients with high-risk cytogenetics (Table 3) have a median OS of <2 3 years despite best available treatments and are candidates for innovative, more aggressive clinical trials.
Indeed, the Clinical Outcome Utilizing Revascularization and Aggressive Drug Evaluation trial (COURAGE) [ 3] and the COURAGE trial nuclear substudy [ 4] have demonstrated that the event-free survival with coronary revascularization was greater than optimal medical therapy in patients with ≥10% ischemic myocardium at baseline and with a reduction of ischemic myocardium ≥5% after treatment.
